TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18165591
Drug: IP ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP ropivacaine 150 mg
Study: 18165591
Drug: IP meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP meperidine 50 mg and ropivacaine 150 mg
Study: 18165591
Drug: Control (IP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (IP saline with IM meperidine 50 mg)
Study: 16517311
Drug: Posterior approach
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior approach injection of bupivacaine, methylprednisolone, and gadolinium-DTPA
Study: 16517311
Drug: Anteromedial approach
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anteromedial approach injection of bupivacaine, methylprednisolone, and gadolinium-DTPA
Study: 14626567
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg + Fenofibrate 200 mg (n = 46)
Study: 14626567
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg + Ciprofibrate 100 mg (n = 40)
Study: 8417220
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream (group 1)
Study: 2874366
Drug: Nasal sprays
Normalized name: SODIUM CHLORIDE 9 mg in 100 mL INTRASINAL AEROSOL, SPRAY [Cleanote Saline Nasal Sprays]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal sprays of dexamethasone, tramazoline, and neomycin
Study: 2874366
Drug: Nasal sprays
Normalized name: SODIUM CHLORIDE 9 mg in 100 mL INTRASINAL AEROSOL, SPRAY [Cleanote Saline Nasal Sprays]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal sprays of dexamethasone and tramazoline with no antibiotic
Study: 24801842
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (18 mg, 27 IU) and Vitamin E acetate (27 mg, 27 IU) delivered via tube-feeding
Study: 24801842
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (18 mg, 27 IU) and Vitamin E acetate (27 mg, 27 IU)
Study: 24801842
Drug: Cubic phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cubic phase formulation
Study: 20133508
Drug: Subcutaneous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous golimumab 50 mg
Study: 20133508
Drug: Subcutaneous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous golimumab 100 mg
Study: 20133508
Drug: Subcutaneous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous golimumab (both doses)
Study: 16435076
Drug: Bisphosphonate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate therapy (10 mg alendronate or 5 mg risedronate) with calcium/vitamin D
Study: 16435076
Drug: Calcium/vitamin D
Normalized name: CALCIUM/VITAMIN D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium/vitamin D treatment alone (control group)
Study: 14984232
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg/day for 2 days, 40 mg/day for 2 days, and 20 mg/day for 2 days) for 6 days
Study: 14984232
Drug: Naratriptan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan (2.5 mg twice a day) during the initial period
Study: 14984232
Drug: Nothing (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nothing (no regular medications) during the initial period
Study: 10858975
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg orally for 14 to 21 days
Study: 30053843
Drug: Adherence Rating
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence Rating Scale (ARS) based on exercise therapy adherence prediction model.
Study: 24912491
Drug: Methylphenidate (intravenous)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (intravenous)
Study: 14640255
Drug: Lipid lowering
Normalized name: Lipid lowering agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid lowering treatment
Study: 7352849
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment beyond short detoxification
Study: 25967707
Drug: Low-nitrogen and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-nitrogen and low-calorie parenteral nutrition combined with enteral nutrition (EN)
Study: 22433704
Drug: Ingavirin combined
Normalized name: Ingavirin
DrugBank: Ingavirin (DB11944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingavirin combined with an antibacterial agent
Study: 19673928
Drug: Prolonged-release (PR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release (PR) torasemide 5 mg
Study: 19673928
Drug: Prolonged-release (PR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release (PR) torasemide 10 mg
Study: 19673928
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) torasemide 5 mg
Study: 19673928
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) torasemide 10 mg
Study: 15089807
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg kg(‐1) ephedrine sulphate
Study: 15089807
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg kg(‐1) ephedrine sulphate
Study: 15089807
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg kg(‐1) ephedrine sulphate
Study: 9626213
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 + Teniposide 100 mg/m2 (arm A)
Study: 9626213
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 (arm B)
Study: 7923659
Drug: c7E3 Fab
Normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: c7E3 Fab (0.25 mg/kg bolus dose)
Study: 7923659
Drug: c7E3 Fab
Normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: c7E3 Fab (continuous infusion for up to 24 hours)
Study: 3197915
Drug: Ampicillin suppository
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin suppository
Study: 3197915
Drug: Amoxycillin suspension
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin suspension
Study: 28241991
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (two 250‐mg tablets of magnesium oxide daily for 8 weeks)
Study: 28241991
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets daily for 8 weeks)
Study: 25727810
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (2000‐4000 IU cholecalciferol) orally daily until delivery
Study: 19837094
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine alone
Study: 19837094
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine plus zinc supplementation
Study: 19837094
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine with zinc supplementation
Study: 9164520
Drug: Endoscopic Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic Injection Sclerotherapy (EIS)
Study: 11499184
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 micrograms)
Study: 11499184
Drug: Intravaginal prostaglandin
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal prostaglandin E2 (4 mg)
Study: 9571345
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment arm aiming for normal HbA1c levels
Study: 9571345
Drug: Phase I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: evening intermediate or long-acting insulin
Study: 9571345
Drug: Phase II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase II: added daytime glipizide (up to 10 mg/day)
Study: 9571345
Drug: Phase III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase III: two injections of insulin alone
Study: 9571345
Drug: Phase IV:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase IV: multiple daily insulin injections
Study: 9571345
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glipizide and insulin (up to 20 mg/day)
Study: 24021517
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (100 μg twice weekly) with cyclic progesterone
Study: 24021517
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches and pills
Study: 18372276
Drug: Warfarin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin for long-term secondary prevention of VTE
Study: 12352277
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (sertraline, desipramine)
Study: 8126147
Drug: Acipimox (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (125 mg, 12 times/24 h)
Study: 2768614
Drug: Client-centered relationship
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centered relationship therapy (RT)
Study: 27862950
Drug: Transdermal 17β‐oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β‐oestradiol (E2) 0.15 mg
Study: 25819860
Drug: Apixaban 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5.0 mg twice daily
Study: 23594968
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg loading dose of prasugrel
Study: 23594968
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg loading dose of prasugrel
Study: 23594968
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg maintenance dose of prasugrel
Study: 23594968
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg maintenance dose of prasugrel
Study: 23594968
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg maintenance dose of prasugrel
Study: 23594968
Drug: Daily 5
Normalized name: Walgreens Gold Seal One Daily 50 Plus Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 5 mg doses of prasugrel
Study: 23594968
Drug: 10 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg, 7.5 mg, and 5 mg doses of prasugrel
Study: 9209661
Drug: Five courses
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five courses of carboplatin 400 mg/m2 or cisplatin 75 mg/m2
Study: 9209661
Drug: Eight courses
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight courses of carboplatin 400 mg/m2 or cisplatin 75 mg/m2
Study: 8429800
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (2 mg oestradiol (E2) and 1 mg norethisterone acetate (NETA) daily)
Study: 8429800
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (2 mg E2 for 12 days, 2 mg E2 and 1 mg NETA for 10 days, and 1 mg E2 for 6 days)
Study: 22525910
Drug: Nomegestrol acetate
Normalized name: nomegestrol acetate
DrugBank: Nomegestrol acetate (DB13981)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Nomegestrol acetate (2.5 mg) and 17β‐E2 (1.5 mg) in a 24‐4‐day regimen
Study: 22525910
Drug: Drospirenone (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone (3.0 mg) and ethinyl E2 (30 micrograms) in a 21‐7‐day regimen
Study: 20635912
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with heat-killed Mycobacterium vaccae (SRL172)
Study: 3739820
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of nicotine
Study: 3739820
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of nicotine
Study: 20332142
Drug: Temsirolimus (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (25 mg)
Study: 20332142
Drug: Temsirolimus (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (15 mg) + IFN-alpha
Study: 10081528
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g given rectally
Study: 7567210
Drug: Inhaled methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methacholine (MCH)
Study: 6778324
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (55 mg/kg/day)
Study: 6778324
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (55 mg/kg/day) and Placebo
Study: 28790113
Drug: SR48692 (NTSR1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR48692 (NTSR1 antagonist) combined with carboplatin
Study: 25801542
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg intravenous fosaprepitant (NKI group)
Study: 25801542
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron (ONS group)
Study: 12464713
Drug: Piracetam up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam up to 1,200 mg/day
Study: 15003745
Drug: Autogenic training
Normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogenic training (AT) for 2 months, weekly sessions
Study: 9566819
Drug: a‐interferon (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: a‐interferon (10 million units then 5 million units three times weekly for 6 to 12 months)
Study: 3338249
Drug: Large protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large protein load (1.35 g/kg)
Study: 3338249
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein load (1.08 g/kg)
Study: 3338249
Drug: Mild protein
Normalized name: mild silver protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild protein load (0.55 g/kg)
Study: 28558062
Drug: AmBisome monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome monotherapy (5 mg/kg single dose)
Study: 28558062
Drug: AmBisome +
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome + paromomycin (5 mg/kg single dose + 10 days of paromomycin at 15 mg/kg/day)
Study: 28558062
Drug: AmBisome +
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome + miltefosine (5 mg/kg single dose + 7 subsequent days of miltefosine at 2.5 mg/kg/day)
Study: 28558062
Drug: Paromomycin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin + miltefosine (10 days of paromomycin at 15 mg/kg/day + miltefosine at 2.5 mg/kg/day)
Study: 27367521
Drug: TB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB treatment
Study: 12020525
Drug: Albuterol inhaler
Normalized name: Albuterol 0.09 MG/1 ACTUATION Inhalation Aerosol Powder [ALBUTEROL INHALER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol inhaler
Study: 16820579
Drug: GIK (40%
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK (40% dextrose, K+ 100 mmol.L(‐1), insulin 70 u.L(‐1); 0.75 mL.kg(‐1).h(‐1) for 6 hours after aortic cross-clamp removal)
Study: 15229965
Drug: human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: human recombinant growth hormone (GH) for 6 months
Study: 9232301
Drug: Sublingual midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sublingual midazolam 7.5 mg
Study: 14591268
Drug: Treatment focusing
Normalized name: ficusin
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment focusing on psychosocial issues
Study: 8545150
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan (Imitrex, Glaxo)
Study: 1675576
Drug: Betaxolol 10
Normalized name: betaxolol 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 10 mg (B10)
Study: 1975196
Drug: Betaxolol 20
Normalized name: betaxolol 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 20 mg (B20)
Study: 1675576
Drug: Betaxolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 40 mg (B40)
Study: 1675576
Drug: Betaxolol 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 80 mg (B80)
Study: 1975196
Drug: Betaxolol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol (all doses)
Study: 28610572
Drug: Intraperitoneal normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal normal saline infusion with pulmonary recruitment maneuver (pressure of 40 cm H2O)
Study: 28610572
Drug: Intraperitoneal normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal normal saline infusion with pulmonary recruitment maneuver
Study: 17998306
Drug: Antidepressant pharmacotherapy
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant pharmacotherapy in comparator trials
Study: 17998306
Drug: Antidepressant pharmacotherapy
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant pharmacotherapy in placebo-controlled trials
Study: 15689713
Drug: Interferon-alpha (IFN-alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-alpha) administered intramuscularly at 9 x 10 IU daily for the first 4 weeks and then three times per week for the next 20 weeks.
Study: 12804846
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms of yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB)
Study: 12804846
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms of yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB)
Study: 11229782
Drug: Antidepressant drugs
Normalized name: MAO A Inhibitors, antidepressant drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant drugs (specific drugs not mentioned)
Study: 7126388
Drug: Propranolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2 to 16 mg)
Study: 7126388
Drug: Labetalol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (10 to 80 mg)
Study: 23581606
Drug: Liquid silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid silicone gel (LSG) applied to hypertrophic scars (HS group)
Study: 23581606
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel alone (control for HS group)
Study: 23581606
Drug: Liquid silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid silicone gel (LSG) applied to minor keloids (KS group)
Study: 22931975
Drug: Sevoflurane at
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane at various concentrations (0.2% to 3.4%) combined with remifentanil (1, 3, 6, and 10 ng/ml)
Study: 22931975
Drug: Sevoflurane and
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane and remifentanil combination
Study: 19778675
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) with apical lead position
Study: 19778675
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) with midventricular lead position
Study: 19778675
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) with basal lead position
Study: 17519258
Drug: Active pulsed
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pulsed magnetic field therapy (PMFT) for 30 min (1.25 Hz, 3 ms width, 600 Gauss)
Study: 17519258
Drug: Sham pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham pulsed magnetic field therapy (deactivated device) for 30 min
Study: 6093524
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g once daily
Study: 15239219
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (second‐generation cephalosporin, broad‐spectrum penicillin or a combination of aminopenicillin and beta‐lactamase inhibitor)
Study: 9875190
Drug: Topical class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical class 3 corticosteroids
Study: 9875190
Drug: Topical class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical class 4 corticosteroids
Study: 9875190
Drug: Oral methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methoxsalen plus sunlight
Study: 9875190
Drug: Oral psoralen
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral psoralen plus sunlight
Study: 9875190
Drug: Oral trioxsalen
Normalized name: Trioxsalen
DrugBank: Trioxsalen (DB04571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral trioxsalen plus sunlight
Study: 9875190
Drug: Oral methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methoxsalen plus UV‐A therapy